{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:04:07Z","timestamp":1788397447600,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Ministry of Science and Higher Education","award":["N402 268836"],"award-info":[{"award-number":["N402 268836"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.psychres.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T12:22:17Z","timestamp":1533903737000},"page":"447-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-1078","authenticated-orcid":false,"given":"Dominik","family":"Strzelecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Urban-Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wysoki\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2018.08.002_bib0001","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0002","first-page":"469","article-title":"Metabolic syndrome\u2013a new world-wide definition","volume":"23","author":"Alberti","year":"2006","journal-title":"Consens. Statement Int. Diabetes Fed. Diabet. Med."},{"key":"10.1016\/j.psychres.2018.08.002_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2016.05.010","article-title":"Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia","volume":"39","author":"Balotsev","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2018.08.002_bib0004","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/bs.apha.2016.01.006","article-title":"The NMDA receptor and schizophrenia: from pathophysiology to treatment","volume":"76","author":"Balu","year":"2016","journal-title":"Adv. Pharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.002_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/157015908785777238","article-title":"The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology","volume":"6","author":"Berthold-Losleben","year":"2008","journal-title":"Curr. Neuropharmacol."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2018.08.002_bib0006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-0173(99)00050-8","article-title":"Network interactions in schizophrenia - therapeutic implications","volume":"31","author":"Carlsson","year":"2000","journal-title":"Brain Res. Rev."},{"issue":"7","key":"10.1016\/j.psychres.2018.08.002_bib0007","first-page":"1311","article-title":"Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)","volume":"19","author":"Chue","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10673229609017192","article-title":"The glutamatergic dysfunction hypothesis for schizophrenia","volume":"3","author":"Coyle","year":"1996","journal-title":"Harv. Rev. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2018.08.002_bib0009","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","article-title":"Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment","volume":"38","author":"Ellaithy","year":"2015","journal-title":"Trends Neurosci."},{"issue":"11","key":"10.1016\/j.psychres.2018.08.002_bib0010","doi-asserted-by":"crossref","first-page":"e27621","DOI":"10.1371\/journal.pone.0027621","article-title":"A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death","volume":"6","author":"Fischer","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yfrne.2011.12.002","article-title":"Cytokines and brain excitability","volume":"33","author":"Galic","year":"2012","journal-title":"Front. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.002_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/13543784.2016.1121995","article-title":"Potential serotonergic agents for the treatment of schizophrenia","volume":"25","author":"Garay","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.psychres.2018.08.002_bib0013","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2018.08.002_bib0014","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2018.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin. Ther. Targ."},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0016","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2018.08.002_bib0017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12888-016-0778-9","article-title":"A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia","volume":"16","author":"Hirayasu","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"Kohler","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2018.08.002_bib0019","first-page":"S153","article-title":"Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls","volume":"24","author":"Kubistova","year":"2012","journal-title":"Psychiatr. Danub."},{"issue":"11","key":"10.1016\/j.psychres.2018.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2018.08.002_bib0021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2018.08.002_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2007.04.038","article-title":"Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study","volume":"63","author":"Lane","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0024","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jagp.2016.09.009","article-title":"Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables","volume":"25","author":"Lee","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","article-title":"Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Lin","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2018.08.002_bib0026","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.schres.2014.09.015","article-title":"Elevated serum levels of TNF-alpha, IL-6 and IL-18 in chronic schizophrenic patients","volume":"159","author":"Luo","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1570159X13666150713174242","article-title":"Metabotropic glutamate 2\/3 receptors and epigenetic modifications in psychotic disorders: a review","volume":"14","author":"Matrisciano","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"26","key":"10.1016\/j.psychres.2018.08.002_bib0028","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.2174\/1381612821666150605105215","article-title":"Serotonin 5-HT1A receptors and antipsychotics - an update in light of new concepts and drugs","volume":"21","author":"McCreary","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.psychres.2018.08.002_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbr.2015.08.037","article-title":"Nicotinic alpha7 and alpha4beta2 agonists enhance the formation and retrieval of recognition memory: potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders","volume":"302","author":"McLean","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.psychres.2018.08.002_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2018.08.002_bib0031","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2017.04.015","article-title":"Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review","volume":"192","author":"Misiak","year":"2018","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.psychres.2018.08.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/289645","article-title":"Chronic inflammation in obesity and the metabolic syndrome","volume":"2010","author":"Monteiro","year":"2010","journal-title":"Med. Inflamm."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.002_bib0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jpsychires.2012.12.010","article-title":"Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia","volume":"47","author":"Noto","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.002_bib0034","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neulet.2011.10.042","article-title":"Association of biomarkers and depressive symptoms in schizophrenia","volume":"505","author":"Noto","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.psychres.2018.08.002_bib0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1389557516666160609081602","article-title":"Beneficial effects of the amino acid glycine","volume":"17","author":"Perez-Torres","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.psychres.2018.08.002_bib0037","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0079-6123(07)63020-9","article-title":"Pro-inflammatory cytokines and their effects in the dentate gyrus","volume":"163","author":"Pickering","year":"2007","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0038","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.autrev.2014.09.001","article-title":"The importance of cytokines and autoantibodies in depression","volume":"14","author":"Postal","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0039","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"40","key":"10.1016\/j.psychres.2018.08.002_bib0040","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.1523\/JNEUROSCI.0530-13.2013","article-title":"TNF-alpha downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABA(A) receptors","volume":"33","author":"Pribiag","year":"2013","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","article-title":"Cytokines sing the blues: inflammation and the pathogenesis of depression","volume":"27","author":"Raison","year":"2006","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.psychres.2018.08.002_bib0042","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1523\/JNEUROSCI.4485-14.2015","article-title":"Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation","volume":"35","author":"Riazi","year":"2015","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.psychres.2018.08.002_bib0043","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ceca.2016.09.005","article-title":"Fast interaction between AMPA and NMDA receptors by intracellular calcium","volume":"60","author":"Rozov","year":"2016","journal-title":"Cell Calcium"},{"issue":"7087","key":"10.1016\/j.psychres.2018.08.002_bib0044","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/nature04671","article-title":"Synaptic scaling mediated by glial TNF-alpha","volume":"440","author":"Stellwagen","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.psychres.2018.08.002_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2015.08.039","article-title":"Supplementation of antipsychotic treatment with sarcosine - GlyT1 inhibitor - causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia","volume":"606","author":"Strzelecki","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"10","key":"10.1016\/j.psychres.2018.08.002_bib0046","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.3390\/nu7105427","article-title":"Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic resonance spectroscopy parameters in left frontal white matter in patients with schizophrenia","volume":"7","author":"Strzelecki","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.psychres.2018.08.002_bib0047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-9255-7-29","article-title":"Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients","volume":"7","author":"Tanni","year":"2010","journal-title":"J. Inflamm."},{"key":"10.1016\/j.psychres.2018.08.002_bib0048","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1742-2094-11-73","article-title":"Peripheral inflammation is associated with remote global gene expression changes in the brain","volume":"11","author":"Thomson","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.psychres.2018.08.002_bib0049","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2014.06.012","article-title":"Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia","volume":"54","author":"Tian","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.002_bib0051","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/08039488.2015.1122079","article-title":"The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia","volume":"70","author":"Turhan","year":"2016","journal-title":"Nordic J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0052","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/pr.113.008144","article-title":"Neuroinflammation and comorbidity of pain and depression","volume":"66","author":"Walker","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psychres.2018.08.002_bib0053","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.irn.2015.08.003","article-title":"Neuronal alpha7 nicotinic receptors as a target for the treatment of schizophrenia","volume":"124","author":"Wallace","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.002_bib0054","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14205\/2312-3710.2014.01.01.3","article-title":"Mechanisms of increased appetite and weight gain induced by psychotropic medications","volume":"1","author":"Wysoki\u0144ski","year":"2014","journal-title":"J. Adv. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2018.08.002_bib0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbi.2015.09.014","article-title":"Interaction of BDNF with cytokines in chronic schizophrenia","volume":"51","author":"Zhang","year":"2016","journal-title":"Brain Behav. Immun."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117318267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117318267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:34:11Z","timestamp":1759037651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178117318267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":55,"alternative-id":["S0165178117318267"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.08.002","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}